XENE - Earnings announcements

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026X-TOLE2 data to be featured in Late Breaking Science oral presentation at AAN Annual Meeting in AprilCompany to host conference call and webcast today at 8:00

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026. Conference Call/Webcast Information:  Date:Monday, March 9, 2026  Time:8:00 am ET (5:00 am PT)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:78

– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing thera

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025. Conference Call/Webcast Information: Date:Monday, November 3, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference I

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializ

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025. Conference Call/Webcast Information: Date: Monday, August 11, 2025Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Webcast: Pre-register hereDial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callersConference ID: 4102397    A live webcas

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in Q3 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-foc

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information:  Date:Monday, May 12, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:5532604   A live webcast of t

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year – Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year – Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025 – Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.

VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025. Conference Call/Webcast Information: Date:Thursday, February 27, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:8120798   A live webcast of the company pre

– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 – Recent appointment of Matt Ronsheim, experienced pharmaceutical executive joining Xenon's senior executive team as Chief Operating Officer – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focuse

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024. Conference Call/Webcast Information: Date: Tuesday, November 12, 2024  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast: Pre-register here   Dial-In:  (800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:7128308 A live webcast of the com

— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025— MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025— Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "We are proud to have the only Kv7

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: Date:Thursday, August 8, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Webcast:Pre-register hereDial-In:(800) 715-9871 toll-free, or (646) 307-1963 for international callersConference ID:1631616   The live audio webcast can be accessed on t

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful "end-of-Phase 2" interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Mr. Ian Mortimer, Xeno

VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024. Conference Call/Webcast Information:  Date:Thursday, May 9, 2024  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In: (800) 715-9871 toll-free, or (646) 307-1963 for international callers   The live audio webcast can be accessed on the Investors section of the Xenon website. Participants are encouraged to pre-register for the conference call in order to

XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025 Planned "end-of-Phase 2" meeting with the FDA in April to support the initiation of XEN1101 Phase 3 program in major depressive disorder in the second half of the year Strong financial position with approximately $930 million to fully support XEN1101 Phase 3 programs in epilepsy and major depressive disorder and expected cash runway into 2027 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Feb. 29, 202

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2023 financial and operating results after the close of U.S. financial markets on Thursday, February 29, 2024. Conference Call/Webcast Information: Date:  Thursday, February 29, 2024Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Dial-In: (800) 715-9871 or (646) 307-1963 for international callersConference ID: 9376408 A live audio webcast will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD. Summary of Efficacy Data The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6. The mean reduction was 13.90 in the placebo group, 15.61 in the XEN1101 10 mg group and 16.94 in t

Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Patient enrollment in X-TOLE2 expected to complete in the second half of 2024 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. Mr. Ian Mortimer

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, November 8, 2023. Conference Call/Webcast Information: Date:Wednesday, November 8, 2023  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Dial-In:(800) 715-9871 or (646) 307-1963 for international callers  Conference ID:4249948   A live audio webcast will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are sub

Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy programs including in X-TOLE2 and X-TOLE3 clinical trials in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Xenon to host XEN1101 MDD Webinar in mid-September to discuss Kv modulation in MDD, the X-NOVA clinical trial and the broader MDD landscape Conference call at 4:30 pm ET today VANCOUVER, British Columbia, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported financ

VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, August 9, 2023. Conference Call/Webcast Information: Date:Wednesday, August 9, 2023Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Dial-In:(800) 715-9871 or (646) 307-1963 for international callersConference ID:7071952   A live audio webcast will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to chang

XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials Anticipate last patient to be screened next month in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in fourth quarter Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. Mr. I

VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Tuesday, May 9, 2023. Conference Call/Webcast Information: Date:Tuesday, May 9, 2023Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Dial-In:(800) 715-9871 or (646) 307-1963 for international callersConference ID:4092363 A live audio webcast will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change. About Xeno

BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 1, 2023. Conference Call/Webcast Information: Date:Wednesday, March 1, 2023  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Dial-In:(800) 715-9871 or (646) 307-1963 for international callers  Conference ID:5740430   A live audio webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above

BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022. Conference Call/Webcast Information:  Date:Tuesday, November 8, 2022  Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)  Listen-Only Audio Webcast:https://edge.media-server.com/mmc/p/s4tct434  Live Call Participant:Registration Link To participate in the live call, please register using the following link (also noted above) to receive dial-in details and a unique PIN code: Register and

BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2022. Conference Call/Webcast Information: Date:     Tuesday, August 9, 2022Time:    4:30 pm Eastern Time (1:30 pm Pacific Time)Dial-In Number: 1-800-715-9871International Dial-In:        1-646-307-1963Conference ID:   6560707 The webcast will also be broadcast live on the "Investors" section of Xenon's website at investor.xenon-pharma.com and posted for replay following the event. The abo

XEN1101 "End of Phase 2" Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer stated, "We are excited by the progress across all of our clinical development p

BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10, 2022. Conference Call/Webcast Information: Date:Tuesday, May 10, 2022  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Dial-In Number:855-779-9075  International Dial-In:631-485-4866  Conference ID:2263884   The webcast will also be broadcast live on the "Investors" section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the e

BURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2021 and provided a corporate update. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer stated, "We made significant progress in 2021, marked by the positive read-out of strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial, which represented a transformative event for Xenon. We have successfully carried this positive momentum into 2022 as we look forward to an end-of-Phase 2 meeting with the FDA in the second quarter and continue to focus on initi

BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update after the close of U.S. financial markets on Tuesday, March 1, 2022. Conference Call/Webcast Information: Xenon will host a conference call and live audio webcast on Tuesday, March 1, 2022 at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the year-end results and to provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial

Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Results from New Sub-Analyses Consistent with Positive Topline Data and Demonstrate Strong Efficacy Across Responder Subgroups and Increased Efficacy in Patients with Less Severe Disease Xenon to Host Conference Call Today at 9:00 am Eastern Time BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that additional positive data from new sub-analyses of the Phase 2b X-TOLE clinical trial will be prese

BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021). Mr. Ian Mortimer, Xenon's President and Chief Executive Officer stated, "We continue to advance our portfolio of neurology-focused programs, and we have a number of scientific presentations scheduled at the AES 2021 meeting in Chicago. In addition, this year we are hosting a symposium focused on our XEN1101 program and the X-TOLE clinical trial results. We are also participating in a joint ind

BURNABY, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 10, 2021. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on Wednesday, November 10, 2021 to discuss the third quarter 2021 financial results and provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-48

All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Xenon to Host Conference Call and Live Webcast Today at 7:30 am Eastern Time BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 – a differentiated Kv7 potassium channel modulator – administered as adjunctive treatment in adult patients with focal epilepsy. The trial met its primar

BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b "X-TOLE" clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time. A conference call and webcast with slides will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713. The above listed dates and times are subject to change. When available, webcasts wil

Topline Data from XEN1101 Phase 2b "X-TOLE" Clinical Trial Anticipated Late September to Mid-October 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer stated, "We continue to make strong progress across our portfolio of proprietary and partnered neurology-focused therapeutic programs. Importantly, we remain on track to report topline data from our XEN1101 Phase 2b X-TOLE study

BURNABY, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021. Xenon management will host a conference call and live audio webcast on Wednesday, August 11, 2021 at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the second quarter 2021 financial results and provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866